Armas Pharmaceuticals, Inc. and Steriscience have today announced an exclusive partnership for the distribution and supply of products for the U.S. market.
FREEHOLD, N.J. , March 17, 2022 /PRNewswire/ -- Armas Pharmaceuticals, Inc. and Steriscience have today announced an exclusive partnership for the distribution and supply of products for the U.S. market. In the first full year of collaboration, Steriscience intends to launch up to eight products through Armas Pharmaceuticals with the first launches in the U.S. market commencing in Q2 2022. The market size of these initial launches generates approximately $431M, according to IQVIA data. “We are excited for Armas to begin our strategics partnership with Steriscience. In addition to the planned launches, our two teams will be working closely to identify areas of product needs based on feedback from our customers. The initial product launches will address common product availability issues.” John Niemi, President & CEO, Armas Pharmaceuticals, Inc. Neeraj Sharma, CEO, Steriscience, stated: “We are pleased to collaborate with Armas Pharmaceuticals for distribution and supply of our products in the U.S. and to provide hospitals and patients with an increased access to critical injectable medicines. This partnership is a step towards solving supply chain constraints in important life-saving antibiotics, anesthetics, and others. Armas Pharmaceuticals industry expertise and strong nationwide distribution network will help us deliver our products to our end user customers.” About Armas Pharmaceuticals, Inc. About Steriscience Contact:
View original content:https://www.prnewswire.com/news-releases/armas-pharmaceuticals-and-steriscience-enter-strategic-partnership-to-commercialize-products-for-the-us-market-301504858.html SOURCE Armas Pharmaceuticals |